Summary of Product Characteristics Updated 11-Jul-2016 | Grunenthal Meds
Adults, elderly and children
Dietary deficiency and as an adjunct in osteoporosis therapy; 2 chewable tablets per day, preferably one tablet each morning and evening.For use in binding phosphate in the management of renal failure in patients on renal dialysis, the dose should be adjusted for the individual patient and is dependent on the serum phosphate level.The tablets should be chewed, not swallowed whole and taken just prior to, during or immediately following a meal.Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcardGrünenthal Meds, Kyowa Kirin International UK NewCo Ltd, Building 6, Galabank Business Park, Galashiels, Borders, TD1 1QH, UK
+44 (0)1896 664 000
+44 (0)1896 664 000
+44 (0)1896 664 000
www.grunenthalmedshub.co.uk
+44 (0)1896 664 001